LEPU ScienTech Medical Technology (HKG:2291) plans to repurchase up to 5.5 million shares using no more than 100 million yuan, subject to shareholder approval, according to a Wednesday Hong Kong bourse filing.
The proposed buyback will be conducted on the open market and funded through existing cash resources, the filing said.
Repurchase prices will not exceed a 5% premium to the average closing price over the five trading days preceding each purchase.